Simvastatin prevents dopaminergic neuronal injury in experimental PD models via activation of NF-kB and MMP 9 and 3

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/514640

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Increasing evidence shows that neuroinflammation may account for dopamine neuron death in Parkinson’s disease (PD). This work aims to provide systematic picture of inflammatory response in PD, and explore anti-inflammatory mechanisms of simvastatin on the progression of PD. We expect that the results may provide a therapeutic strategy using simvastatin via different methods of administration in treating PD, and provide new information about the anti-inflammatory roles of simvastatin.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2009

Funding Scheme: Early Career Fellowships

Funding Amount: $87,937.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Neurology And Neuromuscular Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Matrix metalloproteinases | Neuroinflammation; | Nuclear factor kappa-B (NF-KB); | Parkinson's disease; | Simvastatin;

Related Links